Article Versions Notes

Takagi K, Levy B, Kimmoun A, Miró Ò, Duarte K, Asakage A, Blet A, Deniau B, Schulte J, Hartmann O, et al. Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial. Journal of Clinical Medicine. 2021; 10(19):4512. https://doi.org/10.3390/jcm10194512

Takagi, Koji, Bruno Levy, Antoine Kimmoun, Òscar Miró, Kévin Duarte, Ayu Asakage, Alice Blet, Benjamin Deniau, Janin Schulte, Oliver Hartmann, and et al. 2021. "Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial" Journal of Clinical Medicine 10, no. 19: 4512. https://doi.org/10.3390/jcm10194512

Takagi, K., Levy, B., Kimmoun, A., Miró, Ò., Duarte, K., Asakage, A., Blet, A., Deniau, B., Schulte, J., Hartmann, O., Cotter, G., Davison, B. A., Gayat, E., & Mebazaa, A. (2021). Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial. Journal of Clinical Medicine, 10(19), 4512. https://doi.org/10.3390/jcm10194512